Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Neurology

Demyelinating diseases

Section edited by Francesco Patti and Tjalf Ziemssen

This section covers all types of demyelinating diseases. Topics of interest include, but are not limited to, multiple sclerosis, neuroimmunology, systemic lupus, vasculitis, lymphoma, and myelitis.

Previous Page Page 3 of 11 Next Page
  1. Content type: Research article

    Sexual dysfunction (SD) is very common in people with multiple sclerosis (PwMS) and contributes a significant burden of disease, particularly for young people. SD has direct neurological contributions from dep...

    Authors: Claudia H. Marck, Pia L. Jelinek, Tracey J. Weiland, Jane S. Hocking, Alysha M. De Livera, Keryn L. Taylor, Sandra L. Neate, Naresh G. Pereira and George A. Jelinek

    Citation: BMC Neurology 2016 16:210

    Published on:

  2. Content type: Research article

    Recent studies suggest that cortical lesions in multiple sclerosis (MS) substantially contribute to clinical disease severity. The present study aimed at investigating clinical, neuroanatomical, and cognitive ...

    Authors: Olivia Geisseler, Tobias Pflugshaupt, Ladina Bezzola, Katja Reuter, David Weller, Bernhard Schuknecht, Peter Brugger and Michael Linnebank

    Citation: BMC Neurology 2016 16:204

    Published on:

  3. Content type: Research article

    Acute brainstem syndrome (ABS) may herald multiple sclerosis (MS), neuromyelitis optica (NMO), or occur as an isolated syndrome. The aquaporin 4 (AQP4)-specific serum autoantibody, NMO-IgG, is a biomarker for ...

    Authors: Chen Cheng, Ying Jiang, Xiaodong Lu, Fu Gu, Zhuang Kang, Yongqiang Dai, Zhengqi Lu and Xueqiang Hu

    Citation: BMC Neurology 2016 16:203

    Published on:

  4. Content type: Case report

    Leber’s hereditary optic neuropathy (LHON) co-occuring with multiple sclerosis-like disease (LHON-MS) is suggested to be a separate disease entity denoted Harding’s disease. Little is known about the response ...

    Authors: Trygve Holmøy, Antonie G. Beiske, Svetozar Zarnovicky, Aija Zuleron Myro, Egil Røsjø and Emilia Kerty

    Citation: BMC Neurology 2016 16:197

    Published on:

  5. Content type: Research article

    In the US, the approved multiple sclerosis (MS) oral disease-modifying therapies (ODMTs) are fingolimod (FTY), teriflunomide (TFN), and dimethyl fumarate (DMF). FTY and TFN are recommended with once-daily dose...

    Authors: Tara Nazareth, Howard S. Friedman, Prakash Navaratnam, Denise A. Herriott, John J. Ko, Peri Barr and Rahul Sasane

    Citation: BMC Neurology 2016 16:187

    Published on:

  6. Content type: Research article

    Since the application of MRI scanning to the diagnosis and treatment of multiple sclerosis, it has been recognized that only a small fraction of lesions seen on MRI scans produce recognizable symptoms or neuro...

    Authors: Stanley Cohan, Chiayi Chen, Elizabeth Baraban, Tamela Stuchiner and Lois Grote

    Citation: BMC Neurology 2016 16:184

    Published on:

  7. Content type: Research article

    Due to the preventive nature of disease-modifying therapies for multiple sclerosis, treatment success particularly depends on adherence to therapeutic regimens and patients’ perception of treatment efficacy. T...

    Authors: Uwe Klaus Zettl, Ulrike Bauer-Steinhusen, Thomas Glaser, Klaus Hechenbichler and Michael Hecker

    Citation: BMC Neurology 2016 16:181

    Published on:

  8. Content type: Case report

    Guillain-Barré syndrome is an acquired polyradiculo-neuropathy, often preceded by an antecedent event. It is a monophasic disease but a recurrence rate of 1–6 % is documented in a subset group of patients. Pat...

    Authors: Sonali Sihindi Chapa Gunatilake, Rohitha Gamlath and Harith Wimalaratna

    Citation: BMC Neurology 2016 16:161

    Published on:

  9. Content type: Research article

    Patients with multiple sclerosis (MS) or Crohn’s disease (CD) being treated with natalizumab (Tysabri®, Biogen) who are planning to become pregnant or discover they are pregnant after exposure to natalizumab a...

    Authors: Susan Friend, Sandra Richman, Gary Bloomgren, Lynda M. Cristiano and Madé Wenten

    Citation: BMC Neurology 2016 16:150

    Published on:

  10. Content type: Research article

    Amongst Sardinians the human leukocyte antigen (HLA) DRB1-DQB1 haplotypes *15:02-*06:01, *16:01-*05:02, *14:01-4-*05:03 are protective for multiple sclerosis (MS), while *13:03-*03:01, *04:05-*03:01, *03:01-*0...

    Authors: J. Frau, D. Cossu, C. Sardu, G. Mameli, G. Coghe, L. Lorefice, G. Fenu, S. Tranquilli, L. A. Sechi, M. G. Marrosu and E. Cocco

    Citation: BMC Neurology 2016 16:148

    Published on:

  11. Content type: Research article

    Comprehensive epidemiologic data for multiple sclerosis (MS) in Poland are limited. The aim of this cross-sectional population-based study was to determine the incidence and prevalence of MS in the Swietokrzys...

    Authors: Waldemar Brola, Piotr Sobolewski, Stanisław Flaga, Małgorzata Fudala, Wiktor Szczuchniak, Jan Stoiński, Anita Rosołowska, Jacek Wójcik, Katarzyna Kapica-Topczewska and Danuta Ryglewicz

    Citation: BMC Neurology 2016 16:134

    Published on:

  12. Content type: Research article

    Daclizumab is a humanized monoclonal antibody against CD25 that modulates interleukin 2 signaling. The SELECT TRILOGY of clinical studies (SELECT/SELECTION/SELECTED) evaluated the safety and efficacy of dacliz...

    Authors: Ralf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, Krzysztof Selmaj, Eva Havrdova, Dusan Stefoski, Till Sprenger, Xavier Montalban, Stanley Cohan, Kimberly Umans, Steven J. Greenberg, Gulden Ozen and Jacob Elkins

    Citation: BMC Neurology 2016 16:117

    Published on:

  13. Content type: Research article

    To examine whether past and current reserve-related activities make the brain less susceptible to MS pathology (i.e., lesions or disease-related atrophy).

    Authors: Carolyn E. Schwartz, Michael G. Dwyer, Ralph Benedict, Bianca Weinstock-Guttman, Niels P. Bergsland, Jei Li, Murali Ramanathan and Robert Zivadinov

    Citation: BMC Neurology 2016 16:108

    Published on:

  14. Content type: Study protocol

    Alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, is licensed in Europe since October 2013 as treatment for adult patients with active relapsing-remitting multip...

    Authors: Tjalf Ziemssen, Ulrich Engelmann, Sigbert Jahn, Alexandra Leptich, Raimar Kern, Lina Hassoun and Katja Thomas

    Citation: BMC Neurology 2016 16:109

    Published on:

  15. Content type: Research article

    This retrospective analysis explored prognostic factors associated with a benign multiple sclerosis (BMS) disease course at baseline and over the 4-year follow-up.

    Authors: Robert Zivadinov, Diane L. Cookfair, Lauren Krupp, Aaron E. Miller, Neil Lava, Patricia K. Coyle, Andrew D. Goodman, Burk Jubelt, Michael Lenihan, Joseph Herbert, Malcolm Gottesman, David H. Snyder, Brian R. Apatoff, Barbara E. Teter, Allan B. Perel, Frederick Munschauer…

    Citation: BMC Neurology 2016 16:102

    Published on:

  16. Content type: Research article

    Patients suffering from several neurologic disorders may bear the “stigma” of their disease, being disqualified from full social acceptance. Although stigma is considered to be present in Multiple Sclerosis (M...

    Authors: Maria Anagnostouli, Serafeim Katsavos, Artemios Artemiadis, Markos Zacharis, Paraskevi Argyrou, Ilia Theotoka, Fotini Christidi, Ioannis Zalonis and Ioannis Liappas

    Citation: BMC Neurology 2016 16:101

    Published on:

Previous Page Page 3 of 11 Next Page